Roche’s Genentech Bid Turns Hostile

Roche said it would pay a lower price than it had offered last July for the 44 percent of Genentech it does not already own and that it would go directly to shareholders with its offer.

Original post by By ANDREW POLLACK

Posts Related to Roche’s Genentech Bid Turns Hostile

Genentech Starts Pulling Back Psoriasis Drug
Raptiva, which had 2008 sales of $108 million in the United States, has been linked to a brain infection. Original post by By REUTERS
F.D.A. Panel Supports Avastin to Treat Brain Tumor

Preliminary studies of a blockbuster drug from Roche’s Genentech unit are strong enough to speed its approval for brain cancer, federal cancer experts said. Original ...
Drug Investors Lose Patience
The model of patient biotech investing is being challenged by those who want control of a company’s remains. Original post by By ANDREW POLLACK
A Google Founder’s Gift: Money and His DNA
Sergey Brin says he plans to contribute money and his DNA to a large genetic study of Parkinson’s disease. Original post by By ANDREW POLLACK
In Trial, Drug Eases a Symptom of MS
The results could lead to approval of the first drug to treat a specific symptom of the disease. Original post by By ANDREW POLLACK

Travel Credit Cards

Travel Credit Cards, Travel Insurance Reviews and Travelers Auto Insurance

Roche’s Genentech Bid Turns Hostile

Posts Related to Roche’s Genentech Bid Turns Hostile

Genentech Starts Pulling Back Psoriasis Drug

F.D.A. Panel Supports Avastin to Treat Brain Tumor

Drug Investors Lose Patience

A Google Founder’s Gift: Money and His DNA

In Trial, Drug Eases a Symptom of MS

Leave a Reply Cancel reply